Upadacitinib Shows Feasibility in Palmoplantar Pustulosis
David Gleeson, BM BCH, PhD, calls upadacitinib a feasible option for palmoplantar pustulosis, extending the JAK1 inhibitor's reach into a therapy-resistant dermatosis.
Topic
Jak1
Topic
Topic
Topic
David Gleeson, BM BCH, PhD, calls upadacitinib a feasible option for palmoplantar pustulosis, extending the JAK1 inhibitor's reach into a therapy-resistant dermatosis.